IntroductionFuzzy bumblebees, like tiny orange sheep, flit between the lilies that blanket the understory of an Argentinian forest, fertilizing the flowers and getting nourishment...

This article is the second of four installments in our new series, How Fintech Companies Can Simplify Their Funding Strategy. Read part one on...

Shark Tank star and venture capitalist Kevin O’Leary is weighing in on the state of the crypto bear market, including some of his recent...

Hamilton, Bermuda, Mar 4, 2022 - (ACN Newswire) - Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio(TM) in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio(TM), it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.

"We are excited to greatly expand the distribution of Bentrio and further enlarge our footprint in Asia through this strategic collaboration with Nuance," said Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "As a fast growing, well capitalized company with a growing portfolio of products specifically for the treatment of respiratory disorders, Nuance is an ideal commercialization partner for this important and dynamic region. We are looking forward to working with the Nuance team to launch Bentrio."

"The prevalence of allergic rhinitis in the Chinese Mainland is particularly high, affecting some 246 million patients[1]," commented Mark G. Lotter, CEO and Founder of Nuance. "In addition, viral infections represent another high-volume opportunity for Bentrio in this region, so we are looking forward to launching this promising therapeutic to patients in the Chinese Mainland; as well as Hong Kong, Macau and South Korea. Bentrio(TM) fits well with Nuance's continuous strategic focus in respiratory space."

References
[1] https://doi.org/10.4168/aair.2019.11.2.156

About Bentrio(TM)

Bentrio(TM)(AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio(TM) forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio(TM) was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio(TM) was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.

About Nuance Pharma

Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. Through partnerships with global leading biopharma companies, Nuance has built a leading late-stage portfolio in respiratory and commercial stage portfolio in emergency care and iron deficiency anemia.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore(TM) / SemaPhore(TM) platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio(TM); commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen(R) and Sonsuvi(R), Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval, timing of commercialization and commercial success of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:
Stephen Kilmer
(647) 872-4849
[email protected]

SOURCE: Altamira Therapeutics Ltd.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Immersion cooling has emerged as a rapidly-evolving technique for increasing bitcoin mining rig efficiency, with many pros, cons and details to consider.

pureAir Active HEPA+ with ODOGard® is a Game Changer for Indoor Air Quality JOHNSON CITY, Tenn.–(BUSINESS WIRE)–GreenTech Environmental is introducing a new technology in the air purification industry: pureAir Active HEPA+ with ODOGard, the only air purifiers on the market that feature proprietary ODOGard technology in combination with True HEPA and advanced active air purification […]

The post GreenTech Environmental Introduces New Technology and Product Innovation appeared first on Fintech News.

365 Business Finance aims to quadruple its lending to UK SMEs over the next two years.

Pollen DeFi (https://pollen.id/), the decentralized protocol that facilitates ‘hivemind' weighting of asset pools that back up market-tradable tokens, today revealed their upcoming ‘Incentivised Beta' platform release and details on how the ‘DeFi 2.0' protocol will enable its unique community-managed financial instrument. The ‘Beta' release, which goes live in December, will initially enable users to contribute to the continual balancing and rebalancing of a singular central asset pool that will back up a tradable asset token. The protocol will be open to whitelisted users who can begin building community credibility (in the form of a ‘reputation' score), compete for a position on the community leaderboard, and, in turn, will have a chance to earn mainnet Pollen ($PLN) governance tokens. 

Pollen DeFi aims to push ‘DeFi' into the ‘DeFi 2.0' era by moving beyond institutional imitation and removing centralized “middlemen”; the platform instead empowers user-curated cryptocurrency asset pools that are constantly refined via a merit-based balancing of users' portfolio suggestions. Community members are rewarded for making good decisions and subsequently gain more influence over the dynamically-rebalancing portfolio.  Alternatively, users who would prefer to turn to more qualified traders (based on proven reputation, scored by the platform) can delegate their voting power accordingly. These ‘hivemind approved' asset portfolios then back up ‘asset pool tokens' listed as easily accessible financial instruments capable of outperforming market fluctuations.  

Boosted earlier this year by strategic backers, The Graph and AlphaBit, Pollen DeFi is focused on building the ultimate ‘crypto meritocracy'; the salient, DAO-driven ‘DeFi 2.0' experience leans on the fact that the leadership team merely creates and hones the core technology and UI, ensures platform security, and facilitates user governance and ease of accessibility, while the diversity of opportunities presented within the financial instrument itself result from decentralized, community-contributed portfolio suggestions. Pollen DeFi is powered by two new tokenized assets built specifically with DeFi 2.0 in mind, the Pollen ($PLN) governance token and the native Portfolio Asset Index token ($PAI) which is backed by the total value locked (TVL) of the first and core asset pool on the platform.  Other crypto-communities, influencers, and even top-ranking Pollen DeFi users will be able to propose additional asset pools that will be continually re-balanced by user proposals and support new asset-backed tokens, similar to the $PAI token.

Pollen DeFi's move from Alpha to Beta with a dramatically upgraded protocol design is supported by an already strong community of followers wishing to begin the process of actively contributing to the balancing of the asset pool. Pollen DeFi's open-source protocol and merit-based system empowers the brightest minds in its community and incentivizes them to continually contribute. This means that $PAI token is backed by a continually rebalanced and optimized asset pool which aims to out-smart market fluctuations with overall global community intelligence ideal for the 24/7 nature of the cryptocurrency market.

Pollen DeFi Project Lead and Co-Founder, Philip Verrien, explained, “Our focus has been on rebuilding asset management from the ground up; reducing risk and volatility, while also maximizing yield and creating dynamic opportunity for anyone, regardless of their experience level; [Pollen DeFi] aims to be the embodiment of what we believe will be the next step in DeFi, and reflect the core principles of truly decentralized finance.” Pollen DeFi's community is at the center of it all; Verrien and his team have designed Pollen DeFi to be powerful and easily accessible not only for the experienced crypto traders hoping to receive community accolades and earn $PLN token rewards for sharing their alchemic index ratios, but also, for those crypto-newcomers who are more familiar with curated asset indexes from TradFi and retail crypto environments consisting of pre-vetted coins and tokens - these users will be able to use Pollen ($PLN) governance token or hold $PAI asset pool token to easily be a part of the secure and well-tuned, ‘hivemind-approved' asset portfolio. 

Pollen DeFi focuses on user participation and utility. It is designed to tackle governance and centralization issues commonplace in today's DeFi ecosystem. Focusing heavily on developing community participation incentives, and processes that build toward true decentralization, using the hivemind to put the community in control.

The $PAI token will be the first index token to be launched on the platform with its value tied to the TVL of the core asset pool. $PAI is designed to be a less volatile asset that provides a safer way to participate in the DeFi ecosystem and is designed to weather any market storm as it will be dynamically managed by the community 24/7. $PLN, on the other hand, is the governance token that allows participants to interact with the platform and is rewarded to community members who actively manage the portfolio successfully or delegate to those that do (from a leaderboard). 

Beginning in December, whitelisted users will be able to actively contribute suggestions to Pollen DeFi's first community-managed portfolio and associated asset pool token, Portfolio Asset Index ($PAI); reputation points earned during this part-testnet, part-mainnet ‘Community Release Incentivised Beta' will be ported over as part of full mainnet launch in Q1 2022. This means that whitelisted early adopters who engage with Pollen's ‘Community Release Incentivised Beta' will appear on the leaderboard once the platform is fully live on mainnet.  The Pollen DeFi team will be releasing more information regarding the community release whitelist and details for those that can participate in the coming weeks, in the meantime anyone interested can join Pollen's telegram group (https://t.me/pollen_dao) or follow @PollenDeFi on twitter. 

For more information, please visit pollen.id.

####

About Pollen DeFi

Pollen DeFi (https://pollen.id/), is a first of its kind decentralized asset management ecosystem where the community builds and manages crypto asset portfolios together. Decentralized finance is designed to be by the people, for the people, and Pollen DeFi is acknowledging this by building the first, truly decentralized platform for managing tokenized asset pools. The merit-based DAO provides a reputation-based governance protocol with incentives that leverage the community's collective wisdom to curate asset pools. In this system, all users of the platform stand to benefit from the contribution of the best performing participants. Initially, the Pollen DeFi platform and its Pollen governance token ($PLN) will manage a single asset token, the Portfolio Asset Index ($PAI) token. The $PAI token will be managed 24-7 by the community and is designed to be a low volatility ‘DeFi Lego' which can be used in other protocols in the decentralized finance ecosystem. After Mainnet launch, other communities will be able to create and manage alternative asset tokens via the Pollen DeFi platform.